Prevalencia de anomalías dentarias de número en pacientes de 6 – 21 años atendidos en un centro radiológico. Ica, 2019 – 2020

Esta investigación tuvo como objetivo el determinar la prevalencia de anomalías dentarias de número en pacientes de 6 – 21 años, atendidos en un centro radiológico. Ica, 2019 – 2020. Este estudio es una investigación de tipo básica, cuyo diseño es no experimental, observacional, de tipo descriptivo, retrospectivo y transversal. Se tomó como muestra 2751 radiografías panorámicas digitales. La técnica utilizada fue la observación y el instrumento fue la ficha de recolección de datos. Entre los resultados se encontró que en la prevalencia de anomalías dentarias de número hubo un mayor porcentaje de supernumerario con un 6% que de agenesia con un 4%. Además, se observó que hubo una mayor frecuencia de agenesia en el premolar con 52%, seguido del incisivo lateral con 38%. Por otro lado, la frecuencia de supernumerarios fue mayor en el mesiodens con 65% y en el parapremolar con 30%. Fue más frecuente la agenesia en el sexo femenino con un 56%, mientras que el supernumerario fue más frecuente en el sexo masculino con un 55%, hallándose una relación estadísticamente significativa de un p=0.03. Se llega a la conclusión que la prevalencia de agenesia fue un 4% y la prevalencia de supernumerario fue un 6%

MAYORISTAPE. APP

El proyecto se enfoca en cubrir la necesidad de dos segmentos de clientes que son interdependientes entre si según el modelo de negocio. El primero está conformado por los clientes mayoristas y el segundo por clientes del segmento de bodegas (canal tradicional). En este proyecto el cual se ha bautizado como MayoristaPe. se busca cubrir las necesidades de ambos segmentos a través del uso de la aplicación desde donde las bodegas podrán realizar y gestionar sus compras para abastecer sus comercios, y los mayoristas cuenten con la posibilidad incrementar sus ventas, publicar ofertas y generar valor para sus clientes, logrando crear eficiencia en tiempos y costos en sus comercios. Inicialmente MayoristaPe. se enfocará en la Ciudad de Lima y Callao, donde se ubican la mayor concentración de mercados mayoristas y bodegas, a futuro buscará ampliar a otros puntos estratégicos. Las fuentes de ingreso se generarán a través de un cobro de membresía mensual y/o a través de un porcentaje sobre las ventas, lo que dependerá del segmento en donde se encuentre cada uno.The project focuses on meeting the need of two customer segments that are interdependent with each other according to the business model. The first is made up of wholesale clients and the second by clients of the winery segment (traditional channel). In this project which has been baptized as MayoristaPe. It seeks to meet the needs of both segments through the use of the application from where wineries can make and manage their purchases to supply their stores, and wholesalers have the possibility to increase their sales, publish offers and generate value for their customers, managing to create time and cost efficiency in their businesses. Initially MayoristaPe. will focus on the City of Lima and Callao, where the largest concentration of wholesale markets and warehouses are located, in the future it will seek to expand to other strategic points. The sources of income will be generated through a monthly membership charge and / or through a percentage of sales, which will depend on the segment where each one is located.Trabajo de investigació

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer

PURPOSE: To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer. EXPERIMENTAL DESIGN: Several ovarian cancer cell lines were used for in vitro and in vivo platinum resensitization studies. Changes in DNA methylation and expression levels of TSG and other cancer-related genes in response to SGI-110 were measured by pyrosequencing and RT-PCR. RESULTS: We demonstrate in vitro that SGI-110 resensitized a range of platinum-resistant ovarian cancer cells to cisplatin (CDDP) and induced significant demethylation and reexpression of TSG, differentiation-associated genes, and putative drivers of ovarian cancer cisplatin resistance. In vivo, SGI-110 alone or in combination with CDDP was well tolerated and induced antitumor effects in ovarian cancer xenografts. Pyrosequencing analyses confirmed that SGI-110 caused both global (LINE1) and gene-specific hypomethylation in vivo, including TSGs (RASSF1A), proposed drivers of ovarian cancer cisplatin resistance (MLH1 and ZIC1), differentiation-associated genes (HOXA10 and HOXA11), and transcription factors (STAT5B). Furthermore, DNA damage induced by CDDP in ovarian cancer cells was increased by SGI-110, as measured by inductively coupled plasma-mass spectrometry analysis of DNA adduct formation and repair of cisplatin-induced DNA damage. CONCLUSIONS: These results strongly support further investigation of hypomethylating strategies in platinum-resistant ovarian cancer. Specifically, SGI-110 in combination with conventional and/or targeted therapeutics warrants further development in this setting

Seismic Performance Assessment in Dense Urban Environments: Evaluation of Nonlinear Building-Foundation Systems Using Centrifuge Tests

In dense urban areas, buildings are generally constructed in clusters, forming city blocks. New buildings are designed assuming their response is independent of adjacent buildings, which ignores potentially important structure-soil-structure-interaction (SSSI) effects. Although a few studies have revealed the significance of SSSI effects, validated simulation and design tools do not exist. In this paper, we present the results from the first in a series of centrifuge tests intended to investigate SSSI effects. Results herein are focused on the design and measured response of two model building-foundation systems placed on dense dry Nevada sand and tested at 55-g. The two models represent prototypical nine-story and three-story special moment resisting frame buildings, with the former structure supported by a three-level basement-mat and the later on isolated spread footings. Nonlinear response-history simulations are performed to aid in the design of the models, with particular attention to reproducing prototype building periods and nonlinear characteristics. Yielding of the model buildings is achieved using custom-designed fuses placed strategically throughout the superstructures. At present, the two models are placed as far apart as possible to characterize soil-structure interaction on individual buildings; subsequent experiments will move the structures in near proximity, allowing direct experimental assessment of structuresoil- structure-interaction

Earthquake Input Motions and Seismic Site Response in a Centrifuge Test Examining SFSI Effects

This paper describes the ground motion selection process and reports observed seismic site response and SFSI effects during a dynamic centrifuge test (Test-1). The centrifuge test is the first in a series of tests examining the effects of SFSI in dense urban environments. The objective of Test-1 is to examine SFSI effects for two structures that are located a significant distance apart and essentially isolated. The model structures represent a three-story building founded on spread footings and a nine-story structure founded on a threestory basement. The structures are sited on a dry, dense bed of Nevada Sand. The centrifuge model is subjected to a series of shaking events that represent near-fault and “ordinary” ground motions at a site in Los Angeles. Results show that site periods degrade as ground motion intensity increases with more pronounced degradation observed for near-fault ground motions as compared with ordinary ground motions. Additionally, the results indicate the importance of kinematic effects of embedded structures when considering SFSI effects

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Compound Semiconductor Materials and Devices

Contains table of contents for Part I, table of contents for Section 1, an introduction, reports on fourteen research projects and a list of publications.Defense Advanced Research Projects Agency/National Center for Integrated Photonics TechnologyJoint Services Electronics Program Grant DAAH04-95-1-0038MIT Lincoln LaboratoryNational Science Foundation Graduate FellowshipU.S. Navy - Office of Naval ResearchAT&T Bell Laboratories FellowshipU.S. Army - Ft. MeadeNTT CorporationNational Science FoundationLockheed-Martin Corporatio

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation

Rhinoviruses cause serious morbidity and mortality as the major etiological agents of asthma exacerbations and the common cold. A major obstacle to understanding disease pathogenesis and to the development of effective therapies has been the lack of a small-animal model for rhinovirus infection. Of the 100 known rhinovirus serotypes, 90% (the major group) use human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor and do not bind mouse ICAM-1; the remaining 10% (the minor group) use a member of the low-density lipoprotein receptor family and can bind the mouse counterpart. Here we describe three novel mouse models of rhinovirus infection: minor-group rhinovirus infection of BALB/c mice, major-group rhinovirus infection of transgenic BALB/c mice expressing a mouse-human ICAM-1 chimera and rhinovirus-induced exacerbation of allergic airway inflammation. These models have features similar to those observed in rhinovirus infection in humans, including augmentation of allergic airway inflammation, and will be useful in the development of future therapies for colds and asthma exacerbations